Our study showed that CASP4 expression followed the same trend as macrophage M2 infiltration, suggesting that CASP4 may have an impact on the associated immune cell infiltration, thereby affecting the susceptibility of glioma patients to immunotherapy. The gene discussed is CASP4; the disease is central nervous system cancer.